In a bid to ease drug imports, the Union Health Ministry has mandated that all such units brought into the country must have a minimum one-year residual shelf life remaining at the time of import.
In a gazette notification dated October 29 (Thursday), the ministry will amend Rule 31 of the Drugs Rules, 1945. It will replace the existing requirement that imported drugs must have more than 60 per cent of their approved shelf life remaining at the time of import with a minimum residual shelf life of 12 months.
“The move is aimed at easing import of medicines and simplifying regulatory hurdles as part of its broader push to improve ease of doing business in the sector,” an official in the know told Business Standard.
However, the existing norm of more than 60 per cent residual shelf life will continue to apply to biological products and radiopharmaceuticals due to their specialised nature and public health considerations.
The amendment comes four months after the ministry had sought public and stakeholder comments for the move via a draft notification in June 2026.
The ministry had then said the change is expected to improve pharmaceutical supply-chain efficiency, reduce wastage arising from restrictive shelf-life requirements, and optimise inventory management.
It would also ensure that imported medicines continue to have adequate usable shelf life before expiry.
It had also clarified that the proposal only changes the residual shelf-life requirement at the time of import, and does not affect regulatory standards relating to quality, safety or efficacy of medicines.
Industry executives said moving from a percentage-based calculation to a fixed time threshold will have a compounding effect across the supply chain.
“When compliance becomes more predictable, importers can plan better, warehousing becomes more efficient and fewer medicines are discarded,” a Delhi-based pharma executive said.
